Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma (Iber-KDd)

Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.

Study Overview

• Status: Recruiting
• Conditions: Refractory Multiple Myeloma; Relapsed Multiple Myeloma
• Intervention / Treatment: Drug: Iberdomide; Drug: Carfilzomib; Drug: Daratumumab; Drug: Dexamethasone; Drug: Acetaminophen; Drug: Diphenhydramine; Drug: Montelukast

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Michelle D Armogan; Phone Number: 305-243-7479; Email: mda182@med.miami.edu

Study Locations

• United States
  • Florida
    • Miami, Florida, United States, 33136
      • Recruiting
      • University of Miami
      • Contact: Michelle D Armogan; Phone Number: 305-243-7479; Email: mda182@med.miami.edu
      • Principal Investigator: Carl O Landgren, MD, PhD
      • Principal Investigator: Benjamin Diamond, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patients with histologically confirmed MM with progressive disease according to the IMWG criteria 47 during or within 60 days of their last regimen who have received 1-3 lines of prior therapy (inclusive of a lenalidomide-containing regimen) and have measurable disease within 4 weeks of enrollment based on one of the following:

   • Serum monoclonal protein ≥ 1.0 g/dL
   • Urine monoclonal protein ≥ 200 mg/24 hour
   • Involved serum immunoglobulin free light chains (FLC) ≥ 10 mg/dL AND abnormal kappa/lambda ratio.

   Note: Because the primary endpoint is MRD-negativity rate, per the discretion of the Principal Investigator (PI), patients without measurable disease (e.g., M-spike < 1.0 g/dL) may also be enrolled in line with the IMWG MM response criteria 47.

2. Prior treatment with cluster of differentiation 38 (CD38) -directed therapy is permitted only if all the following are fulfilled:

   • Best response achieved during CD38-directed therapy was ≥ PR.
   • Patient did not progress while receiving CD38-directed therapy or within 60 days of last dose of therapy.
   • Patient did not discontinue CD38-directed therapy due to a related AE.

3. Prior treatment with carfilzomib is permitted only if all the following are fulfilled:

   • Best response achieved during carfilzomib-based therapy was ≥ PR.
   • Patient did not progress while receiving carfilzomib-based therapy or within 60 days of last dose of therapy.
   • Patient did not discontinue carfilzomib due to a related AE.
4. Creatinine Clearance (CrCl) ≥60 ml/min measured within 4 weeks of enrollment. CrCl can be measured or estimated using Cockcroft-Gault method, Modification of Diet in Renal Disease (MDRD), or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae.
5. Age ≥ 18 years at the time of signing the informed consent documentation. Age limit of 75 years.
6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 within 4 weeks of enrollment (Appendix A).
7. Absolute neutrophil count (ANC) ≥ 1.0 K cells/µL, hemoglobin ≥ 8 g/dL, and platelet count ≥ 50 K platelets/µL measured within 4 weeks of enrollment unless cytopenias are deemed to be due to disease at the discretion of the clinical Investigator. Transfusions and administration of growth factors are permissible.
8. Adequate hepatic function with bilirubin < 1.5 x the upper limit of normal (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN measured within 4 weeks of enrollment.
9. All study participants must be able to tolerate one of the following thromboprophylactic strategies: oral factor Xa inhibitors or low molecular weight heparin or alternative anti-coagulant.

10. Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test within 10-14 days and again within 24 hours prior to prescribing of iberdomide for Cycle 1 (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective (barrier) method, at the same time at least 28 days before she starts taking iberdomide without interruption. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.

    • A FCBP is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Females who do not meet the above definition of FCBP should be classified as females not of childbearing potential (FNCBP).

Exclusion Criteria:

1. Patients receiving concurrent systemic treatment for MM with the following exceptions:

   • Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted.
   • Patients may receive kyphoplasty/vertebroplasty for symptomatic vertebral compression fractures.
   • Bone targeting agents are permitted.
   • Concurrent or prior treatment with corticosteroids for indications other than MM is permitted.
   • Focal radiation therapy within 14 days prior to randomization with the exception of palliative radiotherapy for symptomatic management but not on measurable extramedullary plasmacytoma.
   • Prior MM treatments must be concluded with a washout period of 2 weeks from last dose.

2. Patients who are refractory to an anti-CD38-directed regimen:

   • Prior anti-CD38-directed therapy and carfilzomib are permitted as long as above inclusion criteria are met.
3. Patients with plasma cell leukemia.
4. Patients with Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes syndrome (POEMS syndrome).
5. Patients with amyloidosis.

6. Patients with known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal within 4 weeks of enrollment.

   Note: FEV1 testing is required for patients suspected of having COPD, and patients must be excluded if FEV1 < 50% of predicted normal at any time during the study.

7. Pregnant or lactating females. Because there is a potential risk for AEs in nursing infants secondary to treatment of the mother with carfilzomib in combination with iberdomide, pregnant or lactating females are excluded from study participation. These potential risks may also apply to other agents used in this study.
8. Uncontrolled hypertension (ie, systolic blood pressure [BP] > 160 mmHg, diastolic BP > 100 mmHg) or diabetes
9. Patients with active hepatitis B or C infection.

10. Patient is:

    • Seropositive for human immunodeficiency virus (HIV) (Section 10.3.5.1) within 4 weeks of enrollment.
    • Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]) within 4 weeks of enrollment. Patients with resolved infection (i.e., patients who are HBsAg negative but positive for antibodies to hepatitis B core antigen (anti-HBc) and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (RT-PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Patients with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination do not need to be tested for HBV DNA by PCR.
    • Seropositive for hepatitis C (except in the setting of a sustained virologic response (SVR), defined as aviremia at least 12 weeks after completion of antiviral therapy).

    For more information regarding the timing and frequency of hepatitis testing, refer to Section 10.3.5.1.

11. Significant cardiovascular disease with New York Heart Association (NYHA) class III or IV symptoms, symptomatic ischemia, current uncontrolled arrhythmias, screening electrocardiogram (ECG) with corrected QT interval (QTc) of > 470 msec within 4 weeks of enrollment, pericardial disease, or myocardial infarction within 4 months prior to enrollment, and left ventricular ejection fraction (EF) < 40% as assessed by transthoracic echocardiogram (ECHO) within 4 weeks of enrollment. Current unstable angina as determined by history and physical exam, hypertrophic cardiomyopathy or restrictive cardiomyopathy
12. Pulmonary hypertension
13. Has refractory gastrointestinal (GI) disease with refractory nausea/vomiting, inflammatory bowel disease, or bowel resection that would prevent absorption of oral agents
14. Uncontrolled intercurrent illness including but not limited to active infection or psychiatric illness/social situations that would compromise compliance with study requirements
15. Significant neuropathy ≥ Grade 3 with pain at baseline
16. Contraindication to any concomitant medication, including antivirals or anticoagulation
17. Major surgery within 3 weeks prior to first dose
18. Prior treatment with iberdomide
19. For female patients: Patient plans to become pregnant or donate eggs during the Treatment Period and/or required period for contraception use post-last dose of study treatment.
20. For male patients: Patient plans to father a child or donate sperm during the Treatment Period and/or required period for contraception use post-last dose of study treatment.
21. Patients with limited decision-making capacity.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Iber-KDd Combination Therapy; Prior to Iber-KDd combination therapy, participants will receive Acetaminophen, Diphenhydramine and Montelukast therapy per protocol. Participants will receive up to eight (8) 28-day cycles of combination Iberdomide (I), Carfilzomib (K), Daratumumab (D), and Dexamethasone (d) (Iber-KDd) therapy. Participants will receive Iber-KDd combination therapy for approximately 8 months. In the absence of disease progression, participants will continue on to Iber monotherapy. Participants with disease progression will discontinue study therapy but will continue to be followed for up to three (3) years after conclusion of Iber-KDd combination therapy.	Drug: Iberdomide; Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows: Combination therapy: Cycles 1 to 8: 1 mg per day*, Days 1 to 21 every 28 days.; Monotherapy: Cycles 9 to 20: 1 mg per day*, Days 1 to 21 every 28 days. (*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy; Drug: Carfilzomib; Participants will receive Carfilzomib (K) therapy intravenously (IV) as follows: Cycle 1: 20 mg/m2 per dose on Day 1; 56 mg/m2 per dose on Days 8 and 15; Cycles 2 to 8: 56 mg/m2 per dose on Days 1, 8, and 15.; Drug: Daratumumab; Participants will receive Daratumumab (D) therapy subcutaneously (SC) or intravenously (IV) as follows: Cycles 1 and 2: 1800 mg SC or 16 mg/kg IV on Days 1, 8, 15, and 22; Cycles 3 through 6: 1800 mg SC or 16 mg/kg IV on Days 1 and 15; Cycles 7 and 8: 1800 mg SC or 16 mg/kg IV on Day 1.; Drug: Dexamethasone; Participants will receive Dexamethasone (d) therapy either orally (PO) or intravenously (IV) as follows: Cycles 1 and 2: 40 mg/dose on Days 1, 8, and 15; 20 mg/dose on Day 22; Cycles 3 and 4: 40 mg/dose on Days 1, 8, and 15; Cycles 5 through 8: 20 mg/dose on Days 1, 8, and 15.; Drug: Acetaminophen; Participants will receive Acetaminophen orally (PO) prior to Iber-KDd therapy as follows: Cycles 1 and 2: 650 mg/dose on Days 1, 8, 15, and 22; Cycles 3 through 6: 650 mg/dose on Days 1 and 15; Cycles 7 and 8: 650 mg/dose on Day 1.; Drug: Diphenhydramine; Participants will receive Diphenhydramine either orally (PO) or intravenously (IV) prior to Iber-KDd therapy as follows: Cycles 1 and 2: 25 mg/dose on Days 1, 8, 15, and 22; Cycles 3 through 6: 25 mg/dose on Days 1 and 15; Cycles 7 and 8: 25 mg/dose on Day 1.; Drug: Montelukast; Participants will receive Montelukast orally (PO) prior to Iber-KDd as follows: Cycle 1 only: 10 mg/dose, Days 1, 8, 15, and 22, to be administered prior to the first 4 doses of Daratumumab (D).
Experimental: Iber Monotherapy; After completion of Iber-KDd combination therapy, and In the absence of disease progression, participants will then receive up to twelve (12) 28-day cycles of Iberdomide (Iber) monotherapy. Participants will receive Iber monotherapy for up to 12 months or until disease progression. Participants will be followed for up to three (3) years after conclusion of Iber monotherapy. Total study participation is up to five (5) years.	Drug: Iberdomide; Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows: Combination therapy: Cycles 1 to 8: 1 mg per day*, Days 1 to 21 every 28 days.; Monotherapy: Cycles 9 to 20: 1 mg per day*, Days 1 to 21 every 28 days. (*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of MRD-negativity: Iber-KDd Combination therapy.	The rate of minimal residual disease negativity (MRD-negativity) will be reported as the number of participants achieving MRD-negativity after eight cycles of Iber-KDd combination therapy. MRD-negativity is defined as less than one (<1) residual cancer cell detected in 100,000 cells assessed.	Up to 8 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Experiencing Treatment-Related Toxicity After Starting Iber-KDd Combination Therapy	The safety and tolerability of Iber-KDd combination therapy will be assessed and reported as the number of participants experiencing treatment-related toxicity after start of combination therapy, including treatment-related adverse events (AEs) and serious adverse events (SAEs). AEs and SAEs will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5, per physician discretion.	Up to 9 months
Best Response: Iber-KDd Combination Therapy	Best response will be reported as the proportion of participants achieving their greatest response to Iber-KDd combination therapy as follows: Partial response (PR) or better, very good partial response (VGPR) or better, complete response (CR), and stringent complete response (sCR). Response will be assessed using the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma.	Up to 8 months
Overall Response Rate (ORR): Iber-KDd Combination Therapy	Overall response rate (ORR) is defined as the number of participants achieving partial response (PR), very good partial response (VGFR)m complete response (CR) or stringent complete response (sCR) to Iber-KDd combination therapy. Response will be assessed using the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma.	Up to 8 months
Best Response: Iber Monotherapy	Best response will be reported as the proportion of participants achieving their greatest response to Iberdomide monotherapy as follows: Partial response (PR) or better, very good partial response (VGPR) or better, complete response (CR), and stringent complete response (sCR). Response will be assessed using the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma.	Up to 20 months
Overall Response Rate (ORR): Iber Monotherapy	Overall response rate (ORR) is defined as the number of participants achieving partial response (PR), very good partial response (VGFR)m complete response (CR) or stringent complete response (sCR) to Iberdomide monotherapy. Response will be assessed using the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma.	Up to 20 months
Duration of Response (DOR): Iber-KDd Combination Therapy	Duration of Response (DOR) to Iber-KDd combination therapy will be assessed. Duration of response (DOR) is defined as time from response to progression of disease or death, whichever occurs first.	Up to 8 months
Overall Survival (OS)	Overall survival (OS) is defined as the time from date of first dose of study treatment to death from any cause.	Up to 5 years
Progression-Free Survival (PFS)	Progression-free survival (PFS) is defined as time from date of first dose of study treatment to time of progression or death, whichever occurs first.	Up to 5 years
Event-Free Survival (EFS)	Event-free survival (EFS) is defined as time from date of first dose of study treatment until 1) toxicity requiring removal from study, 2) progression, or 3) death, whichever occurs first.	Up to 5 years
Rate of Sustained MRD-negativity.	The rate of sustained minimal residual disease negativity (MRD-negativity) at the completion combination Iber-KDd therapy and 12 cycles of iberdomide monotherapy will be assessed. MRD-negativity is defined as less than one (<1) residual cancer cell detected in 100,000 cells assessed. The number of participants will sustained Response will be assessed using the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma.	Up to 20 months
Rate of MRD-negativity: Iberdomide monotherapy.	The rate of MRD-negativity as best response will be assessed among participants completing Iberdomide monotherapy. The number of participants with MRD-negativity at the 10^-5 sensitivity will be reported. MRD-negativity is defined as less than one (<1) residual cancer cell detected in 100,000 cells assessed. Response will be assessed using the International Myeloma Working Group (IMWG) Response Criteria for Multiple Myeloma.	Up to 20 months
Number of Participants Experiencing Treatment-Related Toxicity After Starting Iberdomide Monotherapy	The safety and tolerability of Iber monotherapy will be assessed and reported as the number of participants experiencing treatment-related toxicity after start of monotherapy, including treatment-related adverse events (AEs) and serious adverse events (SAEs). AEs and SAEs will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5, per physician discretion.	Up to 21 months

Collaborators and Investigators

• Sponsor: Carl Ola Landgren, MD, PhD
• Collaborators: Bristol-Myers Squibb
• Investigators: Principal Investigator: Carl O Landgren, MD, PhD, University of Miami; Principal Investigator: Benjamin Diamond, MD, University of Miami

Study record dates

Study Major Dates

• Study Start (Actual): February 20, 2024
• Primary Completion (Estimated): March 1, 2029
• Study Completion (Estimated): March 1, 2031

Study Registration Dates

• First Submitted: May 31, 2023
• First Submitted That Met QC Criteria: May 31, 2023
• First Posted (Actual): June 9, 2023

Study Record Updates

• Last Update Posted (Actual): March 1, 2024
• Last Update Submitted That Met QC Criteria: February 28, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Immunoproliferative Disorders; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Multiple Myeloma; Neoplasms, Plasma Cell; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Autonomic Agents; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anesthetics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antipyretics; Antineoplastic Agents; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Dermatologic Agents; Hypnotics and Sedatives; Anesthetics, Local; Anti-Asthmatic Agents; Respiratory System Agents; Leukotriene Antagonists; Hormone Antagonists; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 Enzyme Inducers; Anti-Allergic Agents; Sleep Aids, Pharmaceutical; Histamine H1 Antagonists; Histamine Antagonists; Histamine Agents; Antipruritics; Dexamethasone; Montelukast; Daratumumab; Acetaminophen; Diphenhydramine; Promethazine
• Other Study ID Numbers: 20230227

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No